Last reviewed · How we verify
Bramicar HCT
Bramicar HCT is a fixed-dose combination of bromocriptine and hydrochlorothiazide that reduces dopamine antagonism in the hypothalamus while providing diuretic and antihypertensive effects.
Bramicar HCT is a fixed-dose combination of bromocriptine and hydrochlorothiazide that reduces dopamine antagonism in the hypothalamus while providing diuretic and antihypertensive effects. Used for Hypertension with metabolic dysfunction.
At a glance
| Generic name | Bramicar HCT |
|---|---|
| Sponsor | EMS |
| Drug class | Dopamine agonist / Thiazide diuretic combination |
| Target | Dopamine D2 receptor; sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Bromocriptine is a dopamine D2 receptor agonist that helps regulate prolactin and metabolic function, while hydrochlorothiazide is a thiazide diuretic that reduces blood pressure by decreasing fluid volume and peripheral vascular resistance. The combination targets both metabolic and cardiovascular parameters in hypertensive patients.
Approved indications
- Hypertension with metabolic dysfunction
Common side effects
- Dizziness
- Nausea
- Headache
- Hypotension
- Hypokalemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |